Repetitive Immunoadsorption Cycles for Treatment of Severe Atopic Dermatitis

Therapeutic Apheresis and Dialysis

Volumn 19, Issue 3, 2015, Pages 279-287

  Daeschlein, Georg ^a   Scholz, Sebastian ^a   Lutze, Stine ^a   Eming, Ruediger ^b   Arnold, Andreas ^a   Haase, Hermann ^a   Hertl, Michael ^b   Jünger, Michael ^a  

^a UNIVERSITY OF GREIFSWALD   (Germany)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Atopic dermatitis; IgE; Immunoadsorption; SCORAD; Scoring; TheraSorb

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BETAMETHASONE; BETAMETHASONE VALERATE; BLOOD CLOTTING FACTOR; CREATINE; CYCLOSPORIN; DERMATOLOGICAL AGENT; FUSIDIC ACID; HYDROCORTISONE BUTYRATE; HYDROPHILIC UREA; IMMUNOGLOBULIN A; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LANOLIN ALCOHOL; LINIMENTUM AQUOSUM; LIPOPHILIC UREA; POLIDOCANOL; PREDNICARBATE; TACROLIMUS; UNCLASSIFIED DRUG; UREA;

ADOLESCENT; ADSORBER; ADULT; APHERESIS DEVICE; ARTICLE; ATOPIC DERMATITIS; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; DEPRESSED BLOOD PRESSURE; FEMALE; HUMAN; IMMUNOADSORPTION; MALE; MEDICAL DEVICE; MIDDLE AGED; PRIORITY JOURNAL; SCORING ATOPIC DERMATITIS; SKIN DISEASE ASSESSMENT; TREATMENT DURATION; YOUNG ADULT; BLOOD; DERMATITIS, ATOPIC; IMMUNOLOGY; PATHOLOGY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ADOLESCENT; ADULT; DERMATITIS, ATOPIC; FEMALE; HUMANS; IMMUNOGLOBULIN E; IMMUNOSORBENT TECHNIQUES; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84930246607     PISSN: 17449979     EISSN: 17449987     Source Type: Journal    
DOI: 10.1111/1744-9987.12267     Document Type: Article

References (25)

1. Lipozencic J, Wolf R. Atopic dermatitis: an update and review of the literature. Dermatol Clin 2007;25:5-12.
2. Munzenberger PJ, Montejo JM. Safety of topical calcineurin inhibitors for the treatment of atopic dermatitis. Pharmacotherapy 2007;27:20-28.
3. Lebwohl M, Gower T. A safety assessment of topical calcineurin inhibitors in the treatment of atopic dermatitis. Med Gen Med 2006;8:8.
4. Meagher LJ, Wines NY, Cooper AJ. Atopic dermatitis: review of immunopathogenesis and advances in immunosuppressive therapy. Australas J Dermatol 2002;43:47-54.
5. Harper JI, Ahmed I, Barclay G etal. Cyclosporin for severe childhood atopic dermatitis: short course versus continuous therapy. Br J Dermatol 2000;142:52-58.
6. Lee SS, Tan AW, Giam YC. Cyclosporin in the treatment of severe atopic dermatitis: a retrospective study. Ann Acad Med Singapore 2004;33:311-313.
7. Goujon C, Berard F, Dahel K etal. Methotrexate for the treatment of adult atopic dermatitis. Eur J Dermatol 2006;16:155-158.
8. Berth-Jones J, Takwale A, Tan E etal. Azathioprine in severe adult atopic dermatitis: a double-blind, placebo-controlled, crossover trial. Br J Dermatol 2002;147:324-330.
9. Meggitt SJ, Gray JC, Reynolds NJ. Azathioprine dosed by thiopurine methyltransferase activity for moderate-to-severe atopic eczema: a double-blind, randomised controlled trial. Lancet 2006;367:39-46.
10. Murray ML, Cohen JB. Mycophenolate mofetil therapy for moderate to severe atopic dermatitis. Clin Exp Dermatol 2007;32:3-7.
11. Jang IG, Yang JK, Lee HJ etal. Clinical improvement and immunohistochemical findings in severe atopic dermatitis treated with interferon gamma. J Am Acad Dermatol 2000;42:1033-1040.
12. Lane JE, Cheyney JM, Lane TN, Kent DE, Cohen DJ. Treatment of recalcitrant atopic dermatitis with omalizumab. J Am Acad Dermatol 2006;54:68-72.
13. Vigo PG, Girgis KR, Pfuetze BL, Critchlow ME, Fisher J, Hussain I. Efficacy of anti-IgE therapy in patients with atopic dermatitis. J Am Acad Dermatol 2006;55:168-170.
14. Sheinkopf LE, Rafi AW, Do LT, Katz RM, Klaustermeyer WB. Efficacy of omalizumab in the treatment of atopic dermatitis: a pilot study. Allergy Asthma Proc 2008;29:530-537.
15. Taïeb A, Seneschal J, Mossalayi D. Biologics in atopic dermatitis. J Dtsch Dermatol Ges 2012;3:174-179.
16. Kunz B, Oranje AP, Labrèze L etal. Clinical validation and guidelines for the SCORAD index: consensus report of the European Task Force on Atopic Dermatitis. Dermatology 1997;195:10-19.
17. Brun-Strang C, Taïeb A. Management and socio economic impact of atopic dermatitis in France: the Elipanel study. Value Health 2003;6:784.
18. Zuberbier T, Orlow SJ, Paller AS etal. Patient perspectives on the management of atopic dermatitis. J Allergy Clin Immunol 2006;118:226-232.
19. Jacobi A, Antoni C, Manger B etal. Infliximab in the treatment of moderate to severe atopic dermatitis. J Am Acad Dermatol 2005;52:522-526.
20. Takiguchi R, Tofte S, Simpson B etal. Efalizumab for severe atopic dermatitis: a pilot study in adults. J Am Acad Dermatol 2007;56:222-227.
21. Ibler K, Dam TN, Gniadecki R, Kragballe K, Jemec GB, Agner T. Efalizumab for severe refractory atopic eczema: retrospective study on 11 cases. J Eur Acad Dermatol Venereol 2010;24:837-839.
22. Moul DK, Routhouska SB, Robinson MR, Korman NJ. Alefacept for moderate to severe atopic dermatitis: a pilot study in adults. J Am Acad Dermatol 2008;58:984-989.
23. Burmeister GE, Fisher DM, Fuller R. Asthma Human Pharmacokinetics/ Pharmacodynamics of an Interleukin-4 and Interleukin-13 Dual Antagonist. J Clin Pharmacol 2009;49:1025-1036.
24. Oldhoff JM, Darsow U, Werfel T etal. No effect of anti-interleukin-5 therapy (mepolizumab) on the atopy patch test in atopic dermatitis patients. Int Arch Allergy Immunol 2006;141:290-294.
25. Kasperkiewicz M, Schmidt E, Frambach Y etal. Improvement of treatment-refractory atopic dermatitis by immunoadsorption: a pilot study. J Allergy Clin Immunol 2011;127:267-270.